Result of EGM

Oxford Pharmascience Group plc (the "Company")

Result of General Meeting

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reformulate medicines, announces that, at a General Meeting held earlier today, both resolutions were duly passed.

Accordingly, the conditional placing announced on 27 February 2013 is now unconditional in all respects save for admission of the 166,666,667 new ordinary shares of 0.1 pence each. Admission is expected to take place at 8 a.m. on 20 March 2013.

Following Admission, the Company will have 897,536,619 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is therefore 897,536,619 and this figure may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FSA's Disclosure and Transparency Rules.

Nigel Theobald, CEO, commented:

"The Company has made strong progress over the past two years in developing and commercialising its innovative technology platforms and recently raised £2 million to strengthen its position for continuing this effort.

We are delighted to have Invesco on board as a major shareholder. This new placement will raise additional funds to allow us to accelerate our work on commercialising our technology platforms"

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

N+1 Singer

Shaun Dobson/Jenny Wyllie +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The Company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.